Connected Drug Delivery Devices Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

Connected drug delivery devices integrate electronics, sensors, and wireless connectivity into traditional delivery platforms such as inhalers, insulin pens, autoinjectors, and patch pumps, enabling dose logging, reminders, and data sharing with clinicians and caregivers. The global market is estimated at USD 3.11 billion in 2025 and is projected to expand at roughly 19.16% CAGR through the next decade, making it one of the fastest-growing segments within drug delivery. North America currently accounts for the largest revenue share, supported by high chronic disease burden, digital health reimbursement models, and broad smartphone penetration.

• •Global market valued at approximately USD 3.11 billion in 2025.
• •Forecast CAGR of about 19.16% through the forecast window.
• •North America leads on revenue, with Europe and Asia-Pacific as the next-largest regions.

Rising prevalence of asthma, COPD, and diabetes is creating sustained demand for devices that help patients self-manage complex regimens outside clinical settings. Healthcare payers and providers are increasingly rewarding remote monitoring and adherence, which strengthens the value proposition of connected platforms relative to conventional delivery devices. The expansion of 5G networks, Bluetooth Low Energy modules, and cloud-native health platforms is lowering the cost and complexity of adding connectivity to existing drug delivery hardware.

• •Growing chronic disease burden, particularly respiratory and metabolic conditions.
• •Reimbursement and value-based care models that incentivize adherence tracking.
• •Maturing wireless, sensor, and cloud infrastructure enabling cost-effective connectivity.

By product type, the market is typically segmented into connected inhalation devices, connected injection devices (including smart insulin pens and autoinjectors), and connected wearable pumps and patch systems. By application, respiratory diseases and diabetes represent the two largest therapeutic areas, with oncology, autoimmune conditions, and pain management emerging as growth pockets. Geographically, North America leads in adoption, Europe follows with strong public health backing for adherence programs, and Asia-Pacific is the fastest-growing region due to expanding middle-class healthcare access and large diabetic and asthmatic populations.

• •Inhalation and injection devices dominate product mix, with wearables and patch systems rising fastest.
• •Respiratory and diabetes applications account for the majority of installed base.
• •Asia-Pacific is the highest-growth regional market, while North America holds the largest share.

What are the recent trends and outlook?

Artificial intelligence is being layered onto connected device data to predict exacerbations, personalize dosing, and flag non-adherence before clinical events occur. Pharmaceutical sponsors are increasingly embedding connectivity into clinical trials to capture objective dosing data and support regulatory submissions. Looking ahead, miniaturized electronics, longer-life biocompatible power sources, and tighter integration with electronic health records are expected to broaden use cases and push the market well beyond its 2025 base over the coming decade.

• •AI-driven analytics on adherence and physiologic data are becoming a core differentiator.
• •Sponsors are deploying connected devices in clinical trials for objective dose measurement.
• •Next-generation devices will feature smaller form factors, improved battery life, and deeper EHR integration.